Kimberly Ha

At long last.... after 5 years, I can make this announcement here: My first book, BEYOND INHERITANCE, descries a sea change in how we talk about our genes. It comes out in a couple weeks—preorder your copy or audiobook version (narrated by me) today: penguinrandomhouse.com/books/711682/b…

Most drug discovery for aging diseases starts in a plastic dish with young cells. @MartinBJensen and his team at @GordianBio test hundreds of therapies simultaneously in living animals instead. Speaking at UNLOCK 2026. April 22 in SF. unlockscience.ai

⛰️ CONFERENCE HIGHLIGHTS: New data published in the New England Journal of Medicine and presented at #AAD2026 detailed phase 3 VALOR results of #brepocitinib for dermatomyositis. Read more: hubs.li/Q048QhT-0

🚨 VALOR presented at #AAD2026 🔺oral #brepocitinib 30 mg > placebo for treating dermatomyositis in adults on standard therapies 🔺improved muscle pain, skin disease severity, functional disability 🔺improvements as early as week 4 @AADmember healio.com/news/dermatolo…

Original Article: A Phase 3 Trial of Brepocitinib in Dermatomyositis (VALOR trial) nejm.org/doi/full/10.10… #AAD2026 | @AADmember

🗣️Data from #AAD2026 found oral #brepocitinib 30 mg superior to placebo in treating dermatomyositis in adults. Read more & watch the video from Healio Dermatology peer perspective board member, Anthony P. Fernandez, MD, PhD 👇 @AADmember @ClevelandClinic healio.com/news/dermatolo…

Presented at #AAD2026: In the VALOR trial of brepocitinib in adults with dermatomyositis, the 30-mg dose (but not the 15-mg dose) led to greater improvement on a composite myositis index at 52 weeks than placebo. Serious infections were more frequent with the 30-mg dose. Full trial results: nejm.org/doi/full/10.10… @AADmember

Excited to share our phase 3 trial published today in The New England Journal of Medicine evaluating brepocitinib in dermatomyositis. In this randomized, placebo-controlled study—the largest myositis trial to date—brepocitinib 30 mg daily led to significant improvements across a validated composite myositis outcome measure, including skin disease activity, glucocorticoid tapering, and physical function. Three key takeaways: ⚡ Rapid onset of efficacy, with improvements observed as early as week 4 ⏳ Durable response through 52 weeks 🎯 Targeted mechanism modulating the IFN pathway—a central driver of disease—with meaningful steroid-sparing effects These findings support a shift toward more targeted, mechanism-based therapies in dermatomyositis. Grateful to have contributed as a co-first and co-corresponding author to the design and execution of this study, and to the patients and investigators across participating sites who made this work possible. nejm.org/doi/full/10.10…

Priovant details dermatomyositis data behind brepocitinib's priority review $ROIV #AAD2026 firstwordpharma.com/story/7151472

Thank you @FusionFundVC for your support! Curious why we're heating up so fast? Come find out directly at UNLOCK (unlockscience.ai)

🎉 Excited to be ranked #8 on @FastCompany’s 2026 Most Innovative Companies list in #biotech! By enabling scalable #iPSC production with our closed-loop, #AI-driven platform, we’re tackling one of the toughest challenges in #celltherapy manufacturing: fastcompany.com/91497087/biote…

Dr. David Baker, 2024 Nobel Laureate in Chemistry is opening UNLOCK 2026! Dr. Baker's groundbreaking work in computational protein design earned him the Nobel Prize, transforming drug discovery and synthetic biology. April 22 · SF Register → unlockscience.ai

@CellinoBio @FastCompany 🔥🔥🔥

🏆 What an honor! @CellinoBio has been named one of @FastCompany's Most Innovative Companies of 2026! A meaningful milestone that reflects our team’s work to advance personalized #celltherapies at scale. Read more about #FCMostInnovative here: fastcompany.com/most-innovativ…

.@eGenesisBio has been named to @FastCompany’s list of the World’s Most Innovative Companies of 2026. We’re No. 1 in the Biotech category and ranked No. 34 on Fast Company’s2026 World’s 50 Most Innovative Companies list. Read our release: businesswire.com/news/home/2026…

Excited to share we made the @FastCompany Most Innovative Companies 2026 list in the Data Science category. 🔥🔥🔥 View the list: fastcompany.com/most-innovativ… #FCMostInnovative #BCI

Bessemer's Physical AI 50 is now live — our new list spotlighting 50 startups turning robotics and autonomous systems into deployed products. What these leaders share: 🔹World-class teams combining robotics, AI, and systems engineering 🔹Focus on high-value, repeatable use cases 🔹Deep customer partnerships that generate real-world data See the full list ⏩️bessemervp.team/3PNKtWs

Today at GTC confirmed that several companies are planning to either make announcements or share new research at Unlock2026. Super stoked, it’s going to be a fun event for the ai x science community. More to come soon… 🤫 unlockscience.ai

@maxonwifi @endpts Congrats!! 🔥🔥🔥

Career news: I've been promoted to senior reporter. HOORAY! @endpts rocks and I love this newsroom. I'll still be covering large drugmakers and their dealings in Washington, from FDA to Congress to the WH. Tips/memes/rants to mbayer@endpointsnews.com or maxbayer.10 on Signal.

Thrilled to announce Aviv Regev as the keynote speaker for UNLOCK 2026. Former senior leader at the Broad Institute and current head of R&ED at Genentech, Aviv is one of the leading minds in the integration of biology and AI to transform drug discovery. Apr 22 · SF unlockscience.ai